KENALOG

This brand name is authorized in United States. It is also authorized in Canada, Croatia, Estonia, Lithuania, Malta, New Zealand, UK.

Active ingredients

The drug KENALOG contains one active pharmaceutical ingredient (API):

1	Triamcinolone UNII F446C597KA - TRIAMCINOLONE ACETONIDE
	Triamcinolone acetonide is a more potent derivative of triamcinolone and is approximately 8 times more potent than prednisone. Although the precise mechanism of corticosteroid anti-allergic action is unknown, corticosteroids are very effective in the treatment of allergic diseases in man. Also, local injections are thought to have an anti-inflammatory effect.
	Read more about Triamcinolone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KENALOG-10	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H02AB08	Triamcinolone	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN → H02AB Glucocorticoids
Discover more medicines within H02AB08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	01999761, 01999869
EE	Ravimiamet	1008425
GB	Medicines & Healthcare Products Regulatory Agency	27559
HR	Agencija za lijekove i medicinske proizvode	HR-H-363427938
LT	Valstybinė vaistų kontrolės tarnyba	1013970
MT	Medicines Authority	AA770/12401
NZ	Medicines and Medical Devices Safety Authority	113
US	FDA, National Drug Code	0003-0293, 0003-0315, 0003-0494, 10631-093, 50090-0256, 50090-0295, 50090-0819, 63187-661, 70518-2460, 76420-085